Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that incorporate antibodies and gene editing to improve the outcome of this breakthrough treatment for patients. This research by Saad Kenderian, M.B., Ch.B., a consultant in Hematology at Mayo Clinic, is published in Nature Communications.